Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced an 8% price increase over the past week, likely spurred by a positive opinion from the European Medicines Agency (EMA) regarding its RNAi ...

The CHMP’s positive opinion is based on results ... with additional global regulatory submissions planned for 2025. The company’s stock has reflected this positive momentum, delivering a ...

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Pharma stocks Zydus Life, Aurobindo Pharma and Biocon gained up to nearly 3% in trade after they secured regulatory approvals ...

Alnylam said it remains on track to proceed with additional global regulatory submissions for vutrisiran in 2025 and beyond. For More Such Health News, visit rttnews.com. The views and opinions ...

The CHMP’s positive opinion is based on results from the HELIOS ... Vutrisiran has also been approved by the FDA and ANVISA in Brazil for ATTR-CM, with additional global regulatory submissions planned ...

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP ... UK and is under regulatory review ...

Regulatory applications for Calquence plus venetoclax, with or without obinutuzumab, in this setting are currently under review in several countries based on the AMPLIFY results. The AMPLIFY trial ...

Regulatory applications based on the AMPLIFY results are currently under review in several countries. CLL is the most common type of leukaemia in adults, with approximately 27,000 patients ...